 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021. This past fiscal year we made great strides in providing data to support the development of the candidates in our oral hereditary angioedema fran 